SLC7A5 and head and neck squamous cell carcinoma: JPH203, an SLC7A5 (LAT1) inhibitor, which is also highly expressed in HNSCC, has completed phase II clinical trials in advanced biliary tract cancer and has shown promise in the prevention of biliary tract cancer [67].